U.S. markets closed

Cellect Biotechnology Ltd. (APOP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.2800-0.0100 (-0.44%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close2.2900
Open2.2800
Bid2.1900 x 2900
Ask2.3300 x 1100
Day's Range2.2400 - 2.3300
52 Week Range0.4000 - 6.8900
Volume52,925
Avg. Volume170,026
Market Cap2.628M
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Company News for May 12, 2020
    Zacks

    Company News for May 12, 2020

    Companies In The News Are:

  • Nano-Cap Cellect Biotechnology Rips Higher On Medical Cannabis Deal
    Benzinga

    Nano-Cap Cellect Biotechnology Rips Higher On Medical Cannabis Deal

    Shares of thinly-traded nano-cap biotech Cellect Biotechnology Ltd - ADR (NASDAQ: APOP) are advancing strongly Wednesday. The Israeli company said it has entered into a commercial binding Letter of Intent with medical cannabis company Cannadoc to acquire all rights to the use of Cannadoc products for the reduction of opioid use, including accumulated data as well as ongoing and pipeline of clinical trials.Cellect has developed a technology platform called ApoGraft that selects stem cells to improve the safety and efficacy of regenerative medicine and cell therapies, while Cannadoc is a pharma grade medical cannabis company.The agreement also provides for Cannadoc supplying Cellect over the course of the next five years with a minimum of six tons of GMP pharma grade cannabis products valued at $18 million. The agreement also carries an option for a five-year extension until 2029.Related Link: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesAs part of the agreement, Cellect will issue to Cannadoc 1.02372 million ADRs, representing 19% of its diluted share capital. Cellect will use Cannadoc's existing distribution channels for distributing the products."After a long learning process concomitant with developing our clinical pipeline, we chose to enter the medical cannabis field through the strategic alliance with a leading player and focus on the reduction in use of opioid drugs. We believe this alliance will create immense value for the patient community, the company and its shareholders," said Cellect CEO Shai Yarkoni.Merger In The Cards Apart from the strategic commercial agreement, the companies have also signed a non-binding LOI for a full merger.According to the LOI, Cellect will acquire all outstanding Cannadoc shares from its parent InterCure Ltd (OTC: IRCLF), in exchange for additional Cellect ADRs, which will represent about 95% of the merged company.The proposed merger is subject to definitive agreement, board approval and customary closing conditions, including approval by the Israeli Medical Cannabis Agency and Cellect's shareholders.Cellect shares were rising 44% to $32.97 at time of publication.See more from Benzinga * Cellect Biotech Shares Rip On Intention To Award Stem Cell-related Patents In Europe, Israel(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Can Cellect Biotechnology (NASDAQ:APOP) Afford To Invest In Growth?
    Simply Wall St.

    Can Cellect Biotechnology (NASDAQ:APOP) Afford To Invest In Growth?

    We can readily understand why investors are attracted to unprofitable companies. For example, although...